The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

The novel sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin has recently been reported to improve glycemic control in streptozotocin-induced type 1 diabetic rats in an insulin-independent manner, via an increase in urinary glucose output. We investigated the potential of empagliflozin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Sam Tsz Wai, Chen, Lihua, Li, Stephen Yu Ting, Mayoux, Eric, Leung, Po Sing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726656/
https://www.ncbi.nlm.nih.gov/pubmed/26807719
http://dx.doi.org/10.1371/journal.pone.0147391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726656/
https://www.ncbi.nlm.nih.gov/pubmed/26807719
http://dx.doi.org/10.1371/journal.pone.0147391

Ejemplares similares